Back to Journals » OncoTargets and Therapy » Volume 11
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
14,594 | Dovepress* | 9,742+ | 959 | 10,701 | |
PubMed Central* | 4,852 | 274 | 5,126 | ||
Totals | 14,594 | 1,233 | 15,827 | ||
*Since 11 April 2018 |
View citations on PubMed Central and Google Scholar